Enanta Pharmaceuticals, Inc.
ENTA
$13.24
-$0.26-1.93%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -21.60% | 14.96% | 9.76% | 3.55% | 1.91% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -21.60% | 14.96% | 9.76% | 3.55% | 1.91% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -21.60% | 14.96% | 9.76% | 3.55% | 1.91% |
| SG&A Expenses | -5.28% | -15.98% | -29.87% | -29.09% | -25.47% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -15.08% | -26.47% | -26.26% | -24.63% | -11.74% |
| Operating Income | 8.77% | 51.68% | 52.20% | 38.41% | 21.88% |
| Income Before Tax | -6.80% | 45.37% | 47.53% | 36.04% | 20.94% |
| Income Tax Expenses | 24.14% | 100.54% | 105.77% | 108.82% | 107.34% |
| Earnings from Continuing Operations | -6.83% | 42.19% | 46.44% | 35.12% | 19.43% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -6.83% | 42.19% | 46.44% | 35.12% | 19.43% |
| EBIT | 8.77% | 51.68% | 52.20% | 38.41% | 21.88% |
| EBITDA | 9.23% | 54.37% | 55.76% | 41.78% | 25.04% |
| EPS Basic | 21.50% | 57.49% | 60.43% | 35.70% | 20.17% |
| Normalized Basic EPS | 21.52% | 59.82% | 60.19% | 35.99% | 21.67% |
| EPS Diluted | 21.50% | 57.49% | 60.43% | 35.70% | 20.17% |
| Normalized Diluted EPS | 21.52% | 59.82% | 60.19% | 35.99% | 21.67% |
| Average Basic Shares Outstanding | 36.08% | 35.99% | 35.36% | 0.90% | 0.93% |
| Average Diluted Shares Outstanding | 36.08% | 35.99% | 35.36% | 0.90% | 0.93% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |